36 filings
8-K
UROV
Urovant Sciences Ltd.
29 Mar 21
Sumitovant Biopharma Completes Acquisition of Urovant Sciences
8:35am
8-K
UROV
Urovant Sciences Ltd.
24 Mar 21
Submission of Matters to a Vote of Security Holders
4:29pm
8-K
UROV
Urovant Sciences Ltd.
12 Feb 21
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
4:10pm
8-K
UROV
Urovant Sciences Ltd.
11 Feb 21
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
8:05am
8-K
UROV
Urovant Sciences Ltd.
9 Feb 21
Entry into a Material Definitive Agreement
5:00pm
8-K
30w9hy
23 Dec 20
GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences
4:08pm
8-K
du0434plzxe0ekt
24 Nov 20
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of
5:08pm
8-K
kvuppvpisyjlnudzwk4
17 Nov 20
Regulation FD Disclosure
6:04am
8-K
b5lnwflc
13 Nov 20
Sumitovant Biopharma and Urovant Sciences Announce Sumitovant’s Acquisition of Remaining Stake in Urovant
12:00am
8-K
itzfs nvmqk7vb4h
2 Nov 20
Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results
4:11pm
8-K
weqh3s japmob0inlt
7 Oct 20
Entry into a Material Definitive Agreement
8:05am
8-K
7yyfo9mrdto xj8ai59
23 Sep 20
Submission of Matters to a Vote of Security Holders
5:05pm
8-K
6ngtvnv jr3
13 Aug 20
Urovant Sciences Reports Fiscal First Quarter 2020 Results
4:10pm
8-K
1nk z16awddcdx06p
18 Jun 20
Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
4:10pm
8-K
v9wdd4mpojw
18 Jun 20
Entry into a Material Definitive Agreement
8:05am
8-K
9d8rat7 b3xgyg1
2 Jun 20
Regulation FD Disclosure
10:25am
8-K
s4z9npa0oj3n
28 May 20
Entry into a Material Definitive Agreement
5:00pm
8-K
50gein7wb564p3v
27 May 20
Urovant Sciences Appoints James Hindman to Board of Directors
8:05am
8-K
t4rb 7iox
6 Apr 20
Departure of Directors or Certain Officers
5:01pm
8-K
our91i
23 Mar 20
Urovant Sciences Appoints James Robinson as President and Chief Executive Officer
4:05pm